NATHANIEL BROOKS: Open Payments
NPI 1659728731 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,341 in 151 payments from 16 companies in 2025. Trend: 2023 $1,514 · 2024 $2,592 · 2025 $2,341
Food & beverage: $2,230Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 61 | $520 |
| Supernus Pharmaceuticals, Inc. | 18 | $318 |
| Vanda Pharmaceuticals Inc. | 11 | $261 |
| Teva Pharmaceuticals USA, Inc. | 6 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $177 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $167 |
| Otsuka America Pharmaceutical, Inc. | 6 | $161 |
| Lundbeck LLC | 11 | $141 |
| Almatica Pharma LLC | 4 | $91 |
| Axsome Therapeutics, Inc. | 3 | $82 |
Products named: VRAYLAR, Qelbree, REXULTI, FANAPT, TRINTELLIX, CAPLYTA, AUSTEDO XR, LOREEV XR.
Industry payments across AZ — which companies pay providers there.
